$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Medical drugs
Medical drugs
Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Serputinib/Serpatinib (Reto) linked to long-term survival in thyroid cancer
2026-02-01 22:25:32
Check Details
Exploring survival differences with lenvatinib/lenvatinib in recent hepatocellular carcinoma (HCC) trial
2026-02-01 22:25:32
Check Details
Bumetanide Nasal Spray (Bumetanide)-Enbumyst instructions in Chinese
2026-02-01 22:25:32
Check Details
Reasons why fezolinetant is banned in China
2026-02-01 22:25:32
Check Details
GVHD treatments Pegtarazimod and Besudil make international progress
2026-02-01 22:25:32
Check Details
Is Brivaracetam available as a drug in China?
2026-02-01 22:25:32
Check Details
Which is better, obeticholic or deoxycholic acid?
2026-02-01 22:25:32
Check Details
Reimbursement ratio of neratinib/neratinib in 2025
2026-02-01 22:25:32
Check Details
What are the precautions for Bumetanide Nasal Spray (Bumetanide)-Enbumyst
2026-02-01 22:25:32
Check Details
Is tucatinib/tucatinib already on the market in the country?
2026-02-01 22:25:32
Check Details
What are the significant effects of Alpelisib in treatment?
2026-02-01 22:25:32
Check Details
The functions and indications of fostatinib/fotantinib
2026-02-01 22:25:32
Check Details
1
2
...
2048
2049
2050
2051
2052
2053
2054
...
2438
2439
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Olaparib Plus Pembrolizumab Maintenance Therapy for Metastatic Pancreatic Cancer: Findings from the POLAR Phase II Basket Trial
2
From Causes to Treatments—Exploring Medical Breakthroughs
3
IRX4 Transcription Factor: New Research Insights on Colorectal Cancer Treatment Targets
4
New Research Progress on Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Tumor Relationship
5
Tyrosine Kinase and JAK Inhibitors May Increase Keratinocyte Carcinoma Risk: New Research Reveals Drug Safety Findings
6
CLISGen Database: A New Tool for Cell Line Selection in Cancer Genetic Variation Research
7
RAS Targeted Therapy Resistance Breakthrough: mTORC1 is Key, Dalifarnib Combination Therapy Brings Hope
8
ARID1A Gene: A New Breakthrough in Tumor Immunotherapy, Turning "Cold Tumors" Hot
9
User Agreement
10
Herceptin Hylecta treats HER2-positive breast cancer and only needs to be injected subcutaneously and only used once every three weeks
11
What is the most important information I should know about WELIREG?
12
How to take and store WELIREG